Results 51 to 60 of about 28,689 (318)

Plasma inflammatory cytokines and survival of pancreatic cancer patients. [PDF]

, 2018
OBJECTIVES: Inflammation and inflammatory conditions have been associated with pancreatic cancer risk and progression in a number of clinical, epidemiological, and animal model studies.
Babic, A., Barbie, D. A., Brais, L. K., Fuchs, C. S., Kulke, M. H., Morales-Oyarvide, V., Neupane, N. P., Ng, K., Poole, E. M., Rifai, N., Rubinson, D. A., Schnure, N., Welch, M. W., Wolpin, B. M., Wong, K., Yuan, C., Zaman, M. M., Zhang, S.   +17 more
core   +2 more sources

Practical management of myelofibrosis with ruxolitinib [PDF]

Internal Medicine Journal, 2015
AbstractTreatment for the majority of patients with myelofibrosis is primarily based on symptom control as curative allogeneic stem cell transplantation is typically offered only to younger patients, especially those with poor prognosis disease. Around 50% of patients with myelofibrosis have the JAK2V617F mutation, but almost all patients have aberrant
William Stevenson, Simon Durrant, Constantine S. Tam, Phoebe Joy Ho, Phoebe Joy Ho, David M. Ross, Paula Marlton, Paula Marlton, Robert Bird, Robert Bird, Lindsay Dunlop, Lindsay Dunlop, David Ritchie   +12 more
openaire   +4 more sources

Necessity to screen and treat latent tuberculosis before ruxolitinib treatment—Ruxolitinib-associated disseminated tuberculosis: A case report and literature review

IDCases, 2020
Ruxolitinib, a Janus kinase inhibitor, considerably improves symptoms of patients with polycythemia vera and primary or secondary myelofibrosis. However, its association with the development of infectious complications is a concern. Herein, we report the
Nobuyasu Hirai, Kei Kasahara, Shingo Yoshihara, Tomoko Nishimura, Keitaro Omori, Yoshihiko Ogawa, Taku Ogawa, Naokuni Hishiya, Yuki Suzuki, Hisakazu Yano, Masahide Yoshikawa, Keiichi Mikasa   +11 more
doaj   +1 more source

A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies [PDF]

, 2020
With recent advancements in the understanding of vitiligo pathogenesis, Janus kinase (JAK) inhibitors have emerged as a promising new treatment modality, but their effects remain incompletely elucidated.
Alikhan, Mujahed, Jogi, Reena, Nguyen, Julie K, Patel, Anisha B, Schlichte, Megan J   +4 more
core  

Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. [PDF]

, 2018
The myeloma bone marrow microenvironment promotes proliferation of malignant plasma cells and resistance to therapy. Activation of JAK/STAT signaling is thought to be a central component of these microenvironment-induced phenotypes.
Aftab, Blake T, Ferguson, Ian D, Hann, Byron C, Lam, Christine, Lin, Yu-Hsiu T, Liu, Hui, Liu, Jun O, Mariano, Margarette C, Mitsiades, Constantine S, Murnane, Megan, Smith, Geoffrey A, Taunton, Jack, Wiita, Arun P, Wong, Sandy W   +13 more
core   +2 more sources

Management of myelofibrosis after ruxolitinib failure [PDF]

Annals of Hematology, 2020
AbstractMyelofibrosis is a BCR-ABL1–negative myeloproliferative neoplasm characterized by anemia, progressive splenomegaly, extramedullary hematopoiesis, bone marrow fibrosis, constitutional symptoms, leukemic progression, and shortened survival. Constitutive activation of the Janus kinase/signal transducers and activators of transcription (JAK-STAT ...
Harrison, C.N., Schaap, N.P., Mesa, R.A.
openaire   +4 more sources

JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia [PDF]

, 2017
JAK2 abnormalities may serve as target for precision medicines in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). In the current study we performed a screening for JAK2 mutations and translocations, analyzed the clinical outcome and ...
Besselink, N. (Nicolle), Boer, J.M. (Judith), Boer, M.L. (Monique) den, Boeree, A. (Aurélie), de Goffau-Nobel, W. (Willemieke), de Groot-Kruseman, H.A. (Hester A.), Hoogkamer, A.Q. (Alex Q.), Horstmann, M.A. (Martin), Jerchel, I.S. (Isabel S.), Koudijs, M.J. (Marco J.), Pieters, R. (Rob), Steeghs, E.M.P. (Elisabeth M.P.), van de Ven, C. (Cesca), Zwaan, C.M. (Michel)   +13 more
core   +1 more source

Impaired Antibody Response Following the Second Dose of the BNT162b2 Vaccine in Patients With Myeloproliferative Neoplasms Receiving Ruxolitinib

Frontiers in Medicine, 2022
Data on the effect of ruxolitinib on antibody response to severe acute respiratory coronavirus 2 (SARS-CoV-2) vaccination in patients with myeloproliferative neoplasms (MPN) is lacking.
Daisuke Ikeda, Toshiki Terao, Daisuke Miura, Kentaro Narita, Ami Fukumoto, Ayumi Kuzume, Yuya Kamura, Rikako Tabata, Takafumi Tsushima, Masami Takeuchi, Takaaki Hosoki, Kosei Matsue   +11 more
doaj   +1 more source

Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. [PDF]

, 2016
The discovery of JAK2 V617F mutation in the mid-2000s started to fill the gap between clinical presentation of polycythemia vera (PV), first described by Vaquez at the end of the 19th century, and spontaneous erythroid colony formation, reported by ...
Alberio, L., Blum, S., Martins, F.
core   +2 more sources

Ruxolitinib for the Treatment of Essential Thrombocythemia

HemaSphere, 2018
AbstractDeregulated Janus Kinase 2 (JAK2) activation is central to the pathogenesis of most myeloproliferative neoplasms (MPNs), of which essential thrombocythemia (ET) is the most common entity. Patients with ET are risk‐stratified according to their risk of thrombo‐hemorrhagic complications.
Donal P. McLornan, Donal P. McLornan, Natalia Garcia-Curto, Claire N. Harrison, Deepti Radia, Patrick Harrington, Arief Gunawan   +6 more
openaire   +4 more sources